argenx NV ADR (ARGX)vsGyre Therapeutics Inc. (GYRE)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
GYRE
Gyre Therapeutics Inc.
$7.18
+3.46%
HEALTHCARE · Cap: $647.36M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 3534% more annual revenue ($4.24B vs $116.59M). ARGX leads profitability with a 30.5% profit margin vs 4.3%. ARGX trades at a lower P/E of 34.6x. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
GYRE
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
-735.1%
Fair Value
$0.94
Current Price
$7.18
$6.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Revenue surging 33.4% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
1.7% earnings growth
Smaller company, higher risk/reward
4.3% margin — thin
Operating margin of 0.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : GYRE
The strongest argument for GYRE centers on Revenue Growth. Revenue growth of 33.4% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : GYRE
The primary concerns for GYRE are EPS Growth, Market Cap, Profit Margin. A P/E of 336.0x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
ARGX profiles as a growth stock while GYRE is a hypergrowth play — different risk/reward profiles.
GYRE carries more volatility with a beta of 6.92 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 39/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is a biopharmaceutical innovator focused on developing groundbreaking therapies for rare and complex diseases. Leveraging a proprietary platform, the company accelerates the discovery and commercialization of precision treatments tailored to address significant unmet medical needs. With a strong commitment to scientific rigor and patient-centered outcomes, Gyre is strategically positioned to advance its pipeline in gene therapy and precision medicine. Their dedication to research excellence and strategic partnerships highlights their potential for substantial growth in an increasingly competitive biopharmaceutical sector.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?